27525549|t|Undisclosed HIV infection and art use in the kenya AIDS indicator survey 2012: relevance to targets for HIV diagnosis and treatment in kenya
27525549|a|To assess the impact of undisclosed HIV infection and antiretroviral (ARV) therapy (ART) on national estimates of diagnosed HIV and ART coverage in Kenya. HIV-positive dried blood spot samples from Kenya's second AIDS Indicator Survey were tested for an ARV biomarker by liquid chromatography-tandem mass spectrometry. Estimates of diagnosed HIV and ART use based on self-report were compared with those corrected for undisclosed HIV infection and ART use based on ARV testing. Multivariate analysis determined factors associated with undisclosed HIV infection and ART use among persons on ART. Among 559 HIV-positive samples, the ARV biomarker was detected in 42.5% (CI 37.4-47.7). ARV drugs were present in 90.7% (CI 86.1-95.2) reporting HIV-positive status and receiving ART, 66.7% (CI 59.9-73.4) reporting HIV-positive status irrespective of ART use, 21.0% (CI 13.4-28.6) reporting HIV-negative status, and 19.3% (CI 9.0-29.5) reporting no previous HIV test. After correcting for undisclosed HIV infection and ART use, diagnosed HIV increased from 46.9% to 57.2% and ART coverage increased from 31.8% to 42.8%. Undisclosed HIV infection on ART was associated with being aged 25-39 years and not visiting a health provider in the past year, while younger age and higher wealth was associated with undisclosed ART use. Substantial levels of undisclosed HIV infection and ART use while on ART were observed, resulting in diagnosed HIV underestimated by 112,000 persons and ART coverage by 131,000 persons. Supplementing self-reported ART status with objective measures of ART use in national population -based sero-surveys can improve monitoring of treatment targets in countries.
27525549	0	11	Undisclosed	T080	C0439673
27525549	12	25	HIV infection	T047	C0019693
27525549	30	33	art	T061	C1963724
27525549	34	37	use	T169	C0457083
27525549	45	77	kenya AIDS indicator survey 2012	T170	C0038951
27525549	79	88	relevance	T080	C2347946
27525549	92	99	targets	T169	C1521840
27525549	104	117	HIV diagnosis	T060	C0920550
27525549	122	131	treatment	T061	C0087111
27525549	135	140	kenya	T083	C0022558
27525549	144	150	assess	T058	C0184514
27525549	155	161	impact	T080	C4049986
27525549	165	176	undisclosed	T080	C0439673
27525549	177	190	HIV infection	T047	C0019693
27525549	195	223	antiretroviral (ARV) therapy	T061	C1963724
27525549	225	228	ART	T061	C1963724
27525549	233	241	national	T082	C0681788
27525549	242	251	estimates	T081	C0750572
27525549	255	268	diagnosed HIV	T033	C2186509
27525549	273	276	ART	T061	C1963724
27525549	277	285	coverage	T169	C1999244
27525549	289	294	Kenya	T083	C0022558
27525549	296	308	HIV-positive	T033	C2186509
27525549	309	333	dried blood spot samples	T031	C0178913
27525549	339	375	Kenya's second AIDS Indicator Survey	T170	C0038951
27525549	381	387	tested	T169	C0039593
27525549	395	398	ARV	T121	C1979629
27525549	399	408	biomarker	T201	C0005516
27525549	412	458	liquid chromatography-tandem mass spectrometry	T059	C4049918
27525549	460	469	Estimates	T081	C0750572
27525549	473	486	diagnosed HIV	T033	C2186509
27525549	491	494	ART	T061	C1963724
27525549	495	498	use	T169	C0457083
27525549	508	519	self-report	T062	C2700446
27525549	525	533	compared	T052	C1707455
27525549	559	570	undisclosed	T080	C0439673
27525549	571	584	HIV infection	T047	C0019693
27525549	589	592	ART	T061	C1963724
27525549	593	596	use	T169	C0457083
27525549	606	609	ARV	T121	C1979629
27525549	619	640	Multivariate analysis	T081	C0026777
27525549	641	651	determined	T080	C0521095
27525549	652	659	factors	T169	C1521761
27525549	660	675	associated with	T080	C0332281
27525549	676	687	undisclosed	T080	C0439673
27525549	688	701	HIV infection	T047	C0019693
27525549	706	709	ART	T061	C1963724
27525549	710	713	use	T169	C0457083
27525549	720	727	persons	T098	C0027361
27525549	731	734	ART	T061	C1963724
27525549	746	758	HIV-positive	T033	C2186509
27525549	759	766	samples	T031	C0178913
27525549	772	775	ARV	T121	C1979629
27525549	776	785	biomarker	T201	C0005516
27525549	790	798	detected	T033	C0442726
27525549	824	833	ARV drugs	T121	C0599685
27525549	871	893	reporting HIV-positive	T033	C2186509
27525549	905	914	receiving	T080	C1514756
27525549	915	918	ART	T061	C1963724
27525549	941	963	reporting HIV-positive	T033	C2186509
27525549	987	990	ART	T061	C1963724
27525549	991	994	use	T169	C0457083
27525549	1017	1026	reporting	T058	C0700287
27525549	1027	1046	HIV-negative status	T034	C0854048
27525549	1072	1081	reporting	T058	C0700287
27525549	1082	1084	no	T033	C1513916
27525549	1085	1093	previous	T079	C0205156
27525549	1094	1102	HIV test	T059	C1321876
27525549	1125	1136	undisclosed	T080	C0439673
27525549	1137	1150	HIV infection	T047	C0019693
27525549	1155	1158	ART	T061	C1963724
27525549	1159	1162	use	T169	C0457083
27525549	1164	1177	diagnosed HIV	T033	C2186509
27525549	1178	1187	increased	T081	C0205217
27525549	1212	1215	ART	T061	C1963724
27525549	1216	1224	coverage	T169	C1999244
27525549	1225	1234	increased	T081	C0205217
27525549	1256	1267	Undisclosed	T080	C0439673
27525549	1268	1281	HIV infection	T047	C0019693
27525549	1285	1288	ART	T061	C1963724
27525549	1293	1308	associated with	T080	C0332281
27525549	1315	1319	aged	T098	C0001792
27525549	1351	1366	health provider	T097	C0018724
27525549	1391	1402	younger age	T033	C4061789
27525549	1407	1420	higher wealth	T080	C0699759
27525549	1425	1440	associated with	T080	C0332281
27525549	1441	1452	undisclosed	T080	C0439673
27525549	1453	1456	ART	T061	C1963724
27525549	1457	1460	use	T169	C0457083
27525549	1462	1473	Substantial	T078	C0750502
27525549	1474	1480	levels	T080	C0441889
27525549	1484	1495	undisclosed	T080	C0439673
27525549	1496	1509	HIV infection	T047	C0019693
27525549	1514	1517	ART	T061	C1963724
27525549	1518	1521	use	T169	C0457083
27525549	1531	1534	ART	T061	C1963724
27525549	1540	1548	observed	T169	C1441672
27525549	1550	1562	resulting in	T169	C0332294
27525549	1563	1576	diagnosed HIV	T033	C2186509
27525549	1603	1610	persons	T098	C0027361
27525549	1615	1618	ART	T061	C1963724
27525549	1619	1627	coverage	T169	C1999244
27525549	1639	1646	persons	T098	C0027361
27525549	1662	1675	self-reported	T062	C2700446
27525549	1676	1679	ART	T061	C1963724
27525549	1680	1686	status	T080	C0449438
27525549	1692	1710	objective measures	T170	C0870410
27525549	1714	1717	ART	T061	C1963724
27525549	1718	1721	use	T169	C0457083
27525549	1725	1733	national	T082	C0681788
27525549	1734	1744	population	T098	C1257890
27525549	1752	1764	sero-surveys	T058	C0019700
27525549	1769	1776	improve	T033	C0184511
27525549	1777	1787	monitoring	T058	C1283169
27525549	1791	1800	treatment	T061	C0087111
27525549	1801	1808	targets	T169	C1521840
27525549	1812	1821	countries	T083	C0454664